Convergency Provides Life Sciences Companies with a Specialized Approach to High Value Projects

Accelerates clinical trial processes and time to market, while delivering “right-sized” solutions, at a fraction of the cost and time of traditional consulting firms

WHEATON, Ill.–(BUSINESS WIRE)–#biotech—Convergency LLC, a consulting and advisory firm for pharmaceutical, life sciences and other heavily-regulated industries, today announced a new approach for delivering data management and digital transformation services to the life sciences sector. Convergency can uniquely act as an implementer or adviser, while ensuring proposed technical approaches align with business objectives.

Convergency’s core competency includes design and implementation of Integrated Data environments and Clinical Trial Management Decoupling, while developing more effective and efficient processes along the entire drug delivery value chain.

“The life sciences industry, in many cases has forged ahead with multi-million dollar, digital transformation and data management projects, only to be disappointed with technical dead-end results, months or even years down the road,” said Brian Nigl, CEO and founder of Convergency. “Convergency provides life sciences companies with a prudent path forward in a world of uncertainty. We seamlessly connect the avalanche of data scattered over multiple disparate systems within the drug delivery ecosystem, to ensure that data is compliant, integral and available to the right individuals at the right time.”

Convergency’s consultants have decades of experience designing and implementing integrated data environments and reducing drug delivery cycles by 20 to 35 percent. Convergency unlocks the value of data by bringing together process improvement practices (based on Lean Six Sigma practice), data analytics, AI, along with key infrastructure and cloud-based technology in Amazon AWS and Microsoft Azure.

“I chose Convergency to advise and guide us on our three year integrated data analytics project,” said S. Rogers, Director, at a leading Japanese Pharmaceutical Organization. “They have demonstrated on numerous occasions that they are interested in my professional success.”

Demand for Business Process Outsourcing services in Life Sciences is massive and growing. The global Life Sciences BPO market was valued at around US$ 213 Billion in 2018 and is projected to expand at a CAGR at a 7.9% from 2019 to 2027, according to Transparency Market Research (TMR)’s new report titled, Life Sciences BPO Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027.

Value Proposition of Key Convergency Services

• Aids life sciences companies with their digital transformation and evolution into a modern cloud-based world
• Provides real-time analytics and actionable insights for accelerating time to market
• Enables life sciences companies to build out more effective data analytics platforms
• Provides a more effective and efficient approach to integrated data management and decoupling of clinical trials
• Streamlines and optimizes processes on the drug delivery value chain

About Convergency LLC

Convergency is an advisory and consulting firm focused on serving the needs of life sciences, healthcare and financial organizations. Convergency unlocks value in data, revamps processes to lower costs and accelerates time-to-market, while increasing shareholder and patient value. Convergency has a track record of delivering “right-sized” solutions with greater speed and effectiveness than traditional consulting firms.

Convergency was founded by Brian Nigl, who has over 30+ years experience in heavily-regulated industries, helping businesses transform and achieve competitive advantage. Visit www.convergency.cloud for further information. Follow us on social media: LinkedIn, Twitter and Facebook.

Contacts

Media Contact:
James Malone

The DFI Group

(760) 865-0775

[email protected]

David Finkelstein

The DFI Group

(416) 300-4150

[email protected]